Prostaglandin E2

SKU: orb1302168

Description

Prostaglandin E2 (PGE2) is a bioactive lipid mediator regulating inflammation, vascular tone, and smooth muscle function. It is widely used in research to model neuropathic pain and study inflammatory pathways in both in vitro cellular assays and in vivo animal studies.

Research Area

Immunology & Inflammation, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 363-24-6
• MW: 352.47
• Purity: >98%
• Formula: C₂₀H₃₂O₅
• SMILES: CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
• Target: GPCR
• Solubility: Soluble in DMSO (greater than 25 mg/ml) or in Ethanol (greater than 25 mg/ml).

Bioactivity

• Target IC50:
  EP3 receptor:5.4 nM (EC50)|EP1 receptor:74.4 nM (EC50)|EP2 receptor (NPEC cells):67 nM (EC50)|EP4 receptor:7.1 nM (EC50)
• In Vivo:
  METHODS: To test the role of EP2 receptors in the in vivo absorption response, Prostaglandin E2 (3 mg/kg) was injected subcutaneously four times daily for three days into EP2+/+ and EP2-/- mice on a 129/SvEv background. RESULTS: Prostaglandin E2 increased serum calcium from 9.8+/-0.5 to 10.7+/-0.3 mg/dL in EP2+/+ mice but not in EP2-/- mice. METHODS: To study the effects on bone, Prostaglandin E2 (6 mg/kg) was injected subcutaneously into C57BL/6 mice once daily for 3-12 days. RESULTS: Prostaglandin E2-treated mice showed a decrease in trabecular bone volume (BV/TV) at 14 days, indicating increased bone resorption. However, the Prostaglandin E2-treated 3-day group also stimulated bone formation at 14 days due to increased mineral deposition rate (MAR) and bone formation rate (BFR/BS).
  Read more...
• In Vitro:
  METHODS: Human colorectal cancer cells LS-174T were treated with Prostaglandin E2 (0.05-10 μM) for 1-60 min, and the expression levels of target proteins were detected by Western Blot. RESULTS: Prostaglandin E2 induced phosphorylation of Akt as early as 1 min after stimulation, and the activation of Akt reached a maximum within 10 min and persisted until 60 min. The addition of Prostaglandin E2 activated Akt in a dose-dependent manner. METHODS: FDC-like cells were treated with Prostaglandin E2 (1 μM) for 15-120 min, and the expression levels of target proteins were detected by Western Blot. RESULTS: Prostaglandin E2 did not increase p-ERK, but decreased p-ERK at 60 and 120 min. on the contrary, p-p38 increased starting at 15 min and continued to 60 min.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Dinoprost

Compound Identifiers

PubChem CID

5280360